HUE025765T2 - Fokozott immunválasz madárfajokban - Google Patents
Fokozott immunválasz madárfajokban Download PDFInfo
- Publication number
- HUE025765T2 HUE025765T2 HUE10720350A HUE10720350A HUE025765T2 HU E025765 T2 HUE025765 T2 HU E025765T2 HU E10720350 A HUE10720350 A HU E10720350A HU E10720350 A HUE10720350 A HU E10720350A HU E025765 T2 HUE025765 T2 HU E025765T2
- Authority
- HU
- Hungary
- Prior art keywords
- immunomodulator
- challenged
- egg
- study
- coli
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (5)
- FOKOZOTT IAÍ MŰN VÁLASZ MADÁRFAJOKBAN Szsbslste igéstypotuok I. Immuamodulálo készítmény, amely tartalmaz: a. kationon íiposzóma b^tintóeszköz; és b. métesnssv-inolekulát. ahol a; míkieiosav-s-nokkuk izolált, baktértetból szármázó nnkleinsav-vektor in-szeríáll gén nélkül vagy feagttsense. E&éímchm <®h~val provokfe, etedét tattahnazó tyáktops keífetStetőségénel: a lojásank tlöSviUmlRfeltete immannateláléMs^^^ <*« ovo beadásával történő fokozásában történő alkalmazásra,1, Az: I.. igénypottt szaruk· feészámétjy az ott msgteátozott alkalmazásra, ahol a hposzéraá btel&bS" oszkőz a umhilamelIÉIsvezíkiib'lipiddk és exöwlák Kptd# alkotta: csoportból: vákteott lipteket tartótesz,
- 3. Az 1. vagy 2. igénypont szerinti készítmény az oil meghatátozöttatelnatesra, ahol a liposzőasa be-Jütistéeszkoz aXKTIMA és kötetein; DOTAP és koleszterin; DOT1M Mészterí»;· és DDÁB és koleszterin alkotta csoportból választott llpidplmkat tartalmaz.
- 4. Az 03. igénypontok btog%ÍÉ szsriott ké»z|iip&y az ott fenglfetározott alkalmazássá,, ahol a asádé-kísa^pölekslsIINS-íjfezfískh I, Az 1-4. igénypontok bármelyike Szerinti késztetny az olt meghatározott alkaimazásng ahol 0,1-5 Hhkhsgí-shtht: immonmcteialQ készteényt adunk a totásbákiáí ovo.
- 6, Az 1-5. Igénypontok hánnelyike: szezihíl készítmény az ott «t«gha^®s^t alkalmazásra, ahol 1,0 miktognmsm in-mnitmoáulákí készítményt artek & totásnabfe m '7. Az 1-b. Igénypontok bármelyike szedni: készítmény az olt meghatározott alkalmazásra, ahol az im~ mamsKteMlő készítményt az inkahpás 1 g. napján adjnk as etedét torialmszo tyuktojastei;.
- 8, Az !~T igénypothek bátpfelydse szerints készitméssy az ott meghatározott gias hatóanyagot Is tartalmaz, és ahol a biológiai hatóanyag a Mvetkezik hárnreiylke elleni vádehnítí alkalmazott oltóanyag: Matek-betegség vfens (MíW), New Cteteetegsóg vims |NDV}, esí^nnéana vims (CAV), fertőző harsitís vírox CiBDV), fénőző bronchitis virus (1BV). pniykahespesz-víms tHVT}, fertőző íatteotttensklsz -«fess (H.TV), madár enkefeltteelüisz vdtegMjV), teomiSriniB vfms pP¥|, baroml&ofe·· táv madánssdaenzateras (AIM), movhm, madáHenfézistepa ÍÁLV), ssBikníoendolteloszísz vírus (RÉV) madár adesovirns, hsnortáglls enteníisz vims (KE¥) As kotemsméíL %. Az i-k. igénypontok bármelyike szerinti Mszitmeny az ott meghsiátozoíí alkáintazásra, síitől a katio-nos hposzéms bejattatóeszkoz tartalmaz DOTIMböfc és koleaterint. Hl. .Az 1-9. igénypontok bármelyike szerte készteény az ott meghatározott alkalmazásra, provokáló.·? előtti beadásra, II. Az. 1-9. sgérsypontok bártnelyike szerte készítmény az ott meghatátozpít tealmazásra, pmvokáte utásh beadásra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17809909P | 2009-05-14 | 2009-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE025765T2 true HUE025765T2 (hu) | 2016-05-30 |
Family
ID=42357738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10720350A HUE025765T2 (hu) | 2009-05-14 | 2010-05-07 | Fokozott immunválasz madárfajokban |
| HUE15178476A HUE051005T2 (hu) | 2009-05-14 | 2010-05-07 | Fokozott immunválasz madárfajokban |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15178476A HUE051005T2 (hu) | 2009-05-14 | 2010-05-07 | Fokozott immunválasz madárfajokban |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20120064151A1 (hu) |
| EP (2) | EP2992899B1 (hu) |
| JP (1) | JP5679589B2 (hu) |
| KR (2) | KR101966989B1 (hu) |
| CN (2) | CN102427827B (hu) |
| AR (1) | AR076767A1 (hu) |
| AU (1) | AU2010246652B2 (hu) |
| BR (1) | BRPI1010803A2 (hu) |
| CA (1) | CA2761736C (hu) |
| CL (1) | CL2011002808A1 (hu) |
| CO (1) | CO6460752A2 (hu) |
| CR (1) | CR20110595A (hu) |
| DK (2) | DK2429581T3 (hu) |
| EC (1) | ECSP11011448A (hu) |
| ES (2) | ES2808827T3 (hu) |
| HK (1) | HK1168032A1 (hu) |
| HR (2) | HRP20151117T1 (hu) |
| HU (2) | HUE025765T2 (hu) |
| IL (1) | IL215900A (hu) |
| LT (1) | LT2992899T (hu) |
| MX (1) | MX336019B (hu) |
| MY (1) | MY162561A (hu) |
| NI (1) | NI201100196A (hu) |
| NZ (1) | NZ596366A (hu) |
| PE (1) | PE20120903A1 (hu) |
| PL (2) | PL2429581T3 (hu) |
| PT (2) | PT2992899T (hu) |
| RU (1) | RU2570732C9 (hu) |
| SI (2) | SI2992899T1 (hu) |
| SV (1) | SV2011004056A (hu) |
| TW (1) | TWI555846B (hu) |
| UA (1) | UA106076C2 (hu) |
| UY (1) | UY32634A (hu) |
| WO (1) | WO2010130374A1 (hu) |
| ZA (1) | ZA201107827B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2257306B1 (en) * | 2008-03-25 | 2014-05-07 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
| JP6058550B2 (ja) * | 2010-12-22 | 2017-01-11 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ウシの種における免疫応答の増強 |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| CN103721253B (zh) * | 2014-01-02 | 2015-06-10 | 青岛易邦生物工程有限公司 | 一种禽脑脊髓炎和鸡痘二联活疫苗 |
| CA2940794C (en) | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
| JP2018518511A (ja) * | 2015-06-26 | 2018-07-12 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ | 細胞質ｄｎａ監視分子の調節方法 |
| CA2993883A1 (en) * | 2015-07-31 | 2017-02-09 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species |
| JP2018521108A (ja) * | 2015-07-31 | 2018-08-02 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ | 水生種における免疫応答の増強 |
| SG11201900710YA (en) | 2016-07-26 | 2019-02-27 | Bayer Animal Health Gmbh | Increased fertility in bovine species |
| SG11202004773SA (en) | 2017-12-15 | 2020-06-29 | Bayer Animal Health Gmbh | Immunostimulatory compositions |
| CN114467855A (zh) * | 2022-01-14 | 2022-05-13 | 广东海大集团股份有限公司 | 一种多病因气囊炎雏鸡模型的构建方法及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4458630A (en) * | 1982-06-22 | 1984-07-10 | The United States Of America As Represented By The Secretary Of Agriculture | Disease control in avian species by embryonal vaccination |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| CA2365416C (en) * | 1999-03-26 | 2011-06-14 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| US7355092B2 (en) * | 1999-12-27 | 2008-04-08 | Ronald Marquardt | Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens |
| US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| EP2257306B1 (en) * | 2008-03-25 | 2014-05-07 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
-
2010
- 2010-05-07 PT PT151784766T patent/PT2992899T/pt unknown
- 2010-05-07 UA UAA201114824A patent/UA106076C2/uk unknown
- 2010-05-07 CN CN201080021073.9A patent/CN102427827B/zh active Active
- 2010-05-07 NZ NZ596366A patent/NZ596366A/en not_active IP Right Cessation
- 2010-05-07 AU AU2010246652A patent/AU2010246652B2/en active Active
- 2010-05-07 US US13/320,289 patent/US20120064151A1/en not_active Abandoned
- 2010-05-07 PL PL10720350T patent/PL2429581T3/pl unknown
- 2010-05-07 SI SI201032031T patent/SI2992899T1/sl unknown
- 2010-05-07 HU HUE10720350A patent/HUE025765T2/hu unknown
- 2010-05-07 PT PT107203507T patent/PT2429581E/pt unknown
- 2010-05-07 HU HUE15178476A patent/HUE051005T2/hu unknown
- 2010-05-07 RU RU2011150529/15A patent/RU2570732C9/ru active
- 2010-05-07 DK DK10720350.7T patent/DK2429581T3/en active
- 2010-05-07 KR KR1020117029865A patent/KR101966989B1/ko not_active Expired - Fee Related
- 2010-05-07 MY MYPI2011005467A patent/MY162561A/en unknown
- 2010-05-07 DK DK15178476.6T patent/DK2992899T3/da active
- 2010-05-07 ES ES15178476T patent/ES2808827T3/es active Active
- 2010-05-07 CA CA2761736A patent/CA2761736C/en active Active
- 2010-05-07 LT LTEP15178476.6T patent/LT2992899T/lt unknown
- 2010-05-07 KR KR1020177024103A patent/KR20170102379A/ko not_active Ceased
- 2010-05-07 CN CN201510317838.8A patent/CN104906573A/zh active Pending
- 2010-05-07 EP EP15178476.6A patent/EP2992899B1/en active Active
- 2010-05-07 MX MX2011011931A patent/MX336019B/es unknown
- 2010-05-07 BR BRPI1010803-3A patent/BRPI1010803A2/pt not_active Application Discontinuation
- 2010-05-07 PL PL15178476T patent/PL2992899T3/pl unknown
- 2010-05-07 SI SI201031045T patent/SI2429581T1/sl unknown
- 2010-05-07 EP EP10720350.7A patent/EP2429581B1/en active Active
- 2010-05-07 PE PE2011001938A patent/PE20120903A1/es not_active Application Discontinuation
- 2010-05-07 JP JP2012510144A patent/JP5679589B2/ja not_active Expired - Fee Related
- 2010-05-07 ES ES10720350.7T patent/ES2550181T3/es active Active
- 2010-05-07 WO PCT/EP2010/002809 patent/WO2010130374A1/en active Application Filing
- 2010-05-12 AR ARP100101647A patent/AR076767A1/es unknown
- 2010-05-12 TW TW099115052A patent/TWI555846B/zh not_active IP Right Cessation
- 2010-05-12 UY UY0001032634A patent/UY32634A/es not_active Application Discontinuation
-
2011
- 2011-10-25 IL IL215900A patent/IL215900A/en active IP Right Grant
- 2011-10-26 ZA ZA2011/07827A patent/ZA201107827B/en unknown
- 2011-11-10 CL CL2011002808A patent/CL2011002808A1/es unknown
- 2011-11-10 SV SV2011004056A patent/SV2011004056A/es unknown
- 2011-11-10 EC EC2011011448A patent/ECSP11011448A/es unknown
- 2011-11-11 CR CR20110595A patent/CR20110595A/es unknown
- 2011-11-11 NI NI201100196A patent/NI201100196A/es unknown
- 2011-11-11 CO CO11153951A patent/CO6460752A2/es not_active Application Discontinuation
-
2012
- 2012-09-06 HK HK12108738.6A patent/HK1168032A1/zh not_active IP Right Cessation
-
2015
- 2015-10-22 HR HRP20151117TT patent/HRP20151117T1/hr unknown
-
2020
- 2020-09-29 HR HRP20201554TT patent/HRP20201554T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2429581T3 (en) | Improved immune responses in birds | |
| KR101149687B1 (ko) | 가금류의 예방접종 방법 및 조성물 | |
| RU2624037C2 (ru) | Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла | |
| US10851379B2 (en) | Immunostimulatory plasmids | |
| KR20220041142A (ko) | 조류에 점막 투여하기 위한 조성물 | |
| EP3328423B1 (en) | Enhanced immune response in fish | |
| AU2004294810A1 (en) | In ovo vaccination of Campylobacter in avian species | |
| WO2021011465A1 (en) | Method for vaccinating avians against reovirus | |
| EA047648B1 (ru) | Тройная вакцина против avibacterium paragallinarum, вируса птичьего энцефаломиелита и вируса оспы птиц | |
| McFerran | Convntonci vaccines | |
| 벽Ayricuhreondporcstry | NewConceptson5icci IeDeveloprnentforthePollItryDiseases | |
| Han | New Concepts on Vaccine Development for the Poultry Diseases |